drugset / Trial / NCT00138918
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer
Phase 2
Completed
20 enrolled
University of British Columbia
United States Department of Defense · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to assess the effects of combined therapy with androgen ablation and OGX-011 (an antisense to clusterin) given prior to radical prostatectomy on pathologic complete response rates in men with localized prostate cancer and high risk features.
Timeline
- Start
- 2005-06
- Primary completion
- 2008-05-13
- Completion
- 2008-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | custirsen | Antisense oligonucleotide | 640 mg | Intravenous |